SavedAdd your journal

Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2018 / Cilt: 23 - Sayı: 1

Pre-exposure Prophylaxis Against Human Immunodeficiency Virus

Hıv İnfeksiyonundan Korunmada Temas Öncesi Profilaksi

Güle ÇINAR
Serhat BİRENGEL
Pages
1–7
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Current data and studies on pre-exposure prophylaxis were discussed in this review.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, University of Ankara, Ankara, Turkey According to the Center for Disease Control and Prevention (CDC), there were 2.1 million new human immunodeficiency virus (HIV) cases reported worldwide in 2015, which shows that siginificant work needs to be done to prevent the transmission of HIV.
📊
Key Findings & Data:In studies conducted, the incidence of HIV infection in high-risk individuals decreases over 90% when high-risk individuals use pre-exposure prophylaxis (PreP) HIV, tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) safely.
💡
Conclusion & Impact:Current data and studies on pre-exposure prophylaxis were discussed in this review.
🔬Design:Review & Systematic Survey
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, University of Ankara, Ankara, Turkey According to the Center for Disease Control and Prevention (CDC), there were 2.1 million new human immunodeficiency virus (HIV) cases reported worldwide in 2015, which shows that siginificant work needs to be done to prevent the transmission of HIV. Research to date has focused mainly on high-risk men who have sex with men, but many women around the world are also at a high risk for HIV transmissions. In studies conducted, the incidence of HIV infection in high-risk individuals decreases over 90% when high-risk individuals use pre-exposure prophylaxis (PreP) HIV, tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) safely. Current data and studies on pre-exposure prophylaxis were discussed in this review.

Özet

Hastalık Kontrol ve Korunma Merkezi (CDC) verilerine göre, 2015 yılında dünya çapında yaklaşık 2.1 milyon yeni insan immünyetmezlik virüsü (HIV) infeksiyonu olgusu bildirilmiştir. Bu veriler, HIV’ın bulaşmasını önlemek için önemli çalışmaların yapılması gerektiğini göstermektedir. Bugüne kadar yapılan araştırmalar ağırlıklı olarak erkeklerle seks yapan yüksek riskli erkekler üzerinde yoğunlaşmıştır, ancak dünya genelinde birçok kadın da HIV bulaşması açısından yüksek risk altındadır. Yapılan çalışmalarda, sürekli ve düzenli olarak her gün günde bir kez olarak kullanılan tenofovir disoproksil fumarat-emtrisitabin (TDF-FTC)’in HIV’a karşı temas öncesi profilaksi için kullanıldığında, yüksek riskli bireylerde HIV infeksiyonu insidansını %90’ın üzerinde güvenle azalttığı gösterilmiştir. Bu derlemede temas öncesi profilaksi ile ilgili mevcut veriler ve çalışmalar ele alınmıştır.

🔖

Cite This Article

ÇINAR, G., BİRENGEL, S. (2018). Pre-exposure Prophylaxis Against Human Immunodeficiency Virus. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 23 - Sayı: 1, 1–7. https://ajindex.com/articles/224450

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
  2. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083-90.
  3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.
  4. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423-34.
  5. Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis 2015;61:1601-3.
  6. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016;387:53-60.
  7. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al; ANRS IPERGAY Study Group. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015;373:2237-46.
  8. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med 2016;176:75-84.
  9. Smith DK, Van Handel M, Wolitski RJ, Stryker JE, Hall HI, Prejean J, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition-United States, 2015. MMWR Morb Mortal Wkly Rep 2015;64:1291-5. European AIDS Clinical Society (EACS) Guidelines 8.2 January 2017.
  10. Bernstein KT, Liu KL, Begier EM, Koblin B, Karpati A, Murrill C. Same-sex attraction disclosure to health care providers among New York City men who have sex with men: implications for HIV testing approaches. Arch Intern Med 2008;168:1458-64.
  11. Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, et al.